Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data

Keyphrases

• United States 100%
• Claims Data 100%
• Peripheral T-cell Lymphoma 100%
• Economic Burden 100%
• Treatment Burden 100%
• Commercially Insured 100%
• Lymphoma Patients 41%
• Pharmacy Services 16%
• Healthcare Resource Utilization 16%
• Cost Per Patient 16%
• Hospitalization 8%
• Retrospective Cohort Study 8%
• Effective Treatment 8%
• Adult Patients 8%
• Disease Management 8%
• Length of Hospital Stay 8%
• ICD-9 8%
• Patient Selection 8%
• Exclusion Criteria 8%
• Associated Costs 8%
• Overall Cost 8%
• Mean Cost 8%
• Continuum of Care 8%
• Patient-level 8%
• Office Visits 8%
• Utilization Data 8%
• Hospice 8%
• Lymphoma Diagnosis 8%
• Medical Expenditure 8%
• Payer Type 8%
• Administrative Claims Database 8%
• Patient Service 8%
• ER Visits 8%
• Plan Type 8%
• Data Cost 8%
• Service Operations 8%
• Long Length 8%

Medicine and Dentistry

• Peripheral T-Cell Lymphoma 100%
• Health Care Cost 33%
• Retrospective Cohort Study 8%
• Disease Management 8%
• ICD-9-CM 8%
• Effective Treatment 8%